Travelers' Diarrhea and Typhoid Fever
Two travel-related enteric infections — bacterial travelers' diarrhea (mostly ETEC) treated empirically; typhoid (Salmonella Typhi) requires targeted antibiotics and rising resistance awareness.
Also known as: traveler's diarrhea, typhoid fever, enteric fever, Salmonella Typhi, ETEC
Overview
Travelers' diarrhea (TD) is acute diarrheal illness in travelers, most commonly bacterial (enterotoxigenic E. coli [ETEC] predominant; also Campylobacter, Shigella, Salmonella, EAEC), occasionally viral (norovirus) or parasitic. Typhoid fever (enteric fever) is systemic febrile illness caused by Salmonella enterica serotype Typhi (or Paratyphi A/B/C), invading via small bowel Peyer patches.
Epidemiology
TD affects 20-50% of travelers to high-risk regions (South/Southeast Asia, Africa, Latin America). Typhoid: ~11-21 million cases globally yearly, ~5,700 US cases (mostly returning travelers from South Asia). Rising drug resistance — extensively drug-resistant (XDR) typhoid emerged in Pakistan in 2016 and is spreading.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Travelers' Diarrhea and Typhoid Fever outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- Travel to low-sanitation regions
- Consumption of contaminated water, raw produce, undercooked meat/seafood, unpasteurized dairy
- Staying in budget accommodations, street food
- Younger age, achlorhydria, PPI use
- Immunocompromise
- Unvaccinated against typhoid (for typhoid)
Pathophysiology
TD: ETEC adheres to small bowel and secretes heat-labile (LT, cholera-like) and heat-stable (ST) toxins causing secretory diarrhea. Other bacterial pathogens cause inflammatory or invasive disease. Typhoid: S. Typhi invades M cells of Peyer patches, multiplies intracellularly within macrophages, disseminates via reticuloendothelial system, and reseeds the gallbladder and gut — explaining the biphasic clinical course and chronic carrier state.
Clinical presentation
Symptoms
- Travelers' diarrhea (typical onset 4-14 days into travel): ≥3 loose stools/24 h with nausea, cramping, urgency, low-grade fever; usually self-limited in 3-5 days
- Dysentery: bloody/mucoid stools, high fever, tenesmus — suggests Shigella, Campylobacter, EHEC, or amebiasis
- Typhoid fever (incubation 6-30 days): stepwise rising fever to 39-40°C, relative bradycardia (Faget sign), prolonged headache, abdominal pain, constipation (early; diarrhea later in 'pea-soup' form), splenomegaly, rose spots (faint salmon-colored macules on trunk in ~30%), encephalopathy in severe disease
- Intestinal complications (week 3): perforation and hemorrhage at Peyer patches
- Chronic carrier state (~2-5%): persistent shedding from gallbladder; classic 'Typhoid Mary'
Signs / physical exam
- TD: signs of dehydration; non-distended abdomen with diffuse tenderness
- Typhoid: relative bradycardia for degree of fever, hepatosplenomegaly, rose spots (small, faint macules on trunk), altered mental status in severe cases
- Perforation: peritoneal signs, hypotension
Classic findings
Returning traveler from South Asia with stepwise fever, relative bradycardia, rose spots, and abdominal pain — typhoid fever. Traveler with watery, non-bloody diarrhea on day 3 of a trip to a tropical destination — most likely ETEC travelers' diarrhea.
Differential diagnosis
- Viral gastroenteritis — Short duration, vomiting prominent, no inflammatory markers; norovirus on cruise ships
- Giardiasis — Greasy malodorous diarrhea persisting weeks; tinidazole
- Amebiasis (Entamoeba histolytica) — Bloody dysentery, possible liver abscess; metronidazole + luminal agent
- Malaria — Cyclic fevers, thrombocytopenia, returning traveler; blood smears
- Dengue — Retroorbital pain, thrombocytopenia, hemorrhagic features; NS1 antigen
- Leptospirosis — Calf myalgia, conjunctival suffusion, freshwater exposure
- Inflammatory bowel disease — Chronic disease, family history; endoscopy
Diagnostic workup
Diagnostic criteria
Travelers' diarrhea: clinical syndrome + travel history. Typhoid: positive culture (blood, bone marrow, or stool) for Salmonella Typhi.
Labs
- Travelers' diarrhea: stool culture, multiplex PCR panel, O&P if persistent; not routinely needed for mild self-limited illness
- Typhoid: blood cultures (highest yield first week of illness; sensitivity 40-80%), bone marrow culture (highest yield, ~90%, but invasive), stool culture (later in illness), urine culture
- CBC: typhoid often shows normal or low WBC with relative bradycardia; eosinopenia
- CMP, LFTs (mild transaminitis in typhoid)
- Serology (Widal test) — poor specificity; not recommended where culture available
- Malaria smears in febrile returned traveler — coinfection or alternative diagnosis
Imaging
- Abdominal radiograph or CT if perforation suspected (free air, ileal pneumatosis)
- Ultrasound for hepatosplenomegaly, abscess
Diagnostic algorithm
| Syndrome | Likely Pathogen | Treatment | Notes |
|---|---|---|---|
| TD - mild watery | ETEC > other E. coli | ORS ± loperamide | Antibiotics usually unnecessary |
| TD - moderate | ETEC, Campylobacter, Shigella | Azithromycin 1 g x 1 | Preferred in Asia (cipro resistance) |
| TD - severe/dysenteric | Shigella, Campylobacter, EIEC | Azithromycin 1 g x 1 | No loperamide; consider stool studies |
| TD - chronic >14 d | Giardia, Cyclospora, parasites | Targeted therapy | Stool antigen/PCR |
| Typhoid - uncomplicated | Salmonella Typhi | Azithromycin 1 g then 500 mg x 5-7 d | Outpatient if stable |
| Typhoid - severe / hospitalized | Salmonella Typhi (± XDR) | Ceftriaxone 2 g IV x 7-14 d; meropenem for XDR | Add dexamethasone for shock/AMS |
| Chronic typhoid carrier | Salmonella Typhi (gallbladder) | Ciprofloxacin 4-6 wk ± cholecystectomy | Public health implications |
Treatment
First-line
- Travelers' diarrhea — based on severity:
- • Mild: oral rehydration, loperamide (avoid if dysenteric); antibiotics not required
- • Moderate: azithromycin 1 g PO × 1 (or 500 mg daily × 1-3 days) — preferred globally given fluoroquinolone resistance, especially in Asia for Campylobacter
- • Alternative: ciprofloxacin 500 mg PO BID × 1-3 days (avoid in Asia due to Campylobacter resistance); rifaximin 200 mg PO TID × 3 days (non-absorbed; good for non-invasive ETEC; not effective for invasive infection)
- • Severe/dysenteric: azithromycin 1 g PO × 1 (preferred) — covers Shigella, Campylobacter; do NOT use loperamide
- Typhoid fever:
- • Azithromycin 1 g PO × 1 then 500 mg daily × 5-7 days for uncomplicated outpatient cases
- • Ceftriaxone 2 g IV daily × 7-14 days for severe disease or hospitalized patients
- • Carbapenems (meropenem) for XDR strains from Pakistan
- • Dexamethasone for severe disease with shock/altered mental status (reduces mortality)
- • Fluoroquinolones (ciprofloxacin) historically first-line but increasing resistance — reserve for known susceptible strains
Second-line / adjunct
- Prevention — food and water precautions ('boil it, cook it, peel it, or forget it'); typhoid vaccine for travelers to endemic areas (inactivated Vi polysaccharide IM single dose or live attenuated oral Ty21a 4-dose regimen)
- Chemoprophylaxis: rifaximin for high-risk short-term travelers with comorbidities (not routinely recommended due to resistance concerns)
- Bismuth subsalicylate 524 mg QID — modestly effective TD prophylaxis; many side effects
- Chronic typhoid carriers: prolonged ciprofloxacin (4-6 weeks) or cholecystectomy
Complications
- Travelers' diarrhea: dehydration; persistent post-infectious IBS (~5-10%); reactive arthritis; rarely Guillain-Barre after Campylobacter
- Typhoid: intestinal perforation/hemorrhage (Peyer patch ulceration, week 3), encephalopathy, myocarditis, pneumonia, hepatitis, chronic gallbladder carrier state
- Antimicrobial-resistant typhoid (MDR, XDR) — treatment failure
- HUS from EHEC (avoid antibiotics if EHEC suspected — increases HUS risk)
PANCE pearls
- Azithromycin has displaced ciprofloxacin as first-line for moderate-severe travelers' diarrhea — Campylobacter fluoroquinolone resistance is high in South and Southeast Asia.
- Loperamide is safe in non-bloody, non-febrile TD as adjunctive symptom relief; avoid in dysentery or invasive disease.
- Stepwise rising fever, relative bradycardia, and rose spots in a returned traveler from South Asia — think typhoid; obtain blood cultures BEFORE antibiotics.
- XDR typhoid (resistant to ampicillin, TMP-SMX, fluoroquinolones, third-gen cephalosporins) requires carbapenems — increasingly imported from Pakistan.
- Typhoid vaccination is recommended for any traveler to South Asia, sub-Saharan Africa, or other typhoid-endemic regions; inactivated vaccine is single-dose IM.
References
- CDC Yellow Book 2024 — Travelers' Diarrhea and Typhoid and Paratyphoid Fever chapters
- ISTM 2017 — Riddle et al., Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report
- IDSA 2017 — Shane et al., 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea (Clin Infect Dis)
- WHO Typhoid — WHO Guidelines for the management of typhoid fever (most recent edition)
Practice Infectious Disease questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.